Article
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.
Journal of acquired immune deficiency syndromes (1999) - 1 Jul 2000
Chaix C, Grenier-Sennelier C, Clevenbergh P, Durant J, Schapiro J M, Dellamonica P, Durand-Zaleski I
Abstract excerpt
BACKGROUND: Costs of antiretroviral therapy for HIV-infected patients have increased at a time when most countries are attempting to contain health care costs. Part of this increase results from HIV drug resistance associated with virologic failure and a subsequent shift to more complex and costly therapies. Genotypic guided treatment is associated with better virologic outcome. However, it is not yet known...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.